• At the 19th ISGE Congress, Mithra and Gedeon Richter presented the clinical results of Estelle® to an international scientific audience
  • While Estetrol (E4) has recently been designated as a 'New Active Substance' by the European Medicines Agency (EMA), doctors there have confirmed their strong interest in the use of E4 in contraception.

Liege, Belgium, 3 December, 2020 - 7:30 CET - Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health today announces that physicians at the 19th Congress of the International Society of Gynecologic Endocrinology (ISGE) expressed a strong interest in the clinical results of Estelle®, Mithra's novel combined oral contraceptive (COC) candidate.

Read the press release

Attachments

  • Original document
  • Permalink

Disclaimer

Mithra Pharmaceuticals SA published this content on 03 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 December 2020 06:34:04 UTC